

#### EURAMOS-1: Poor Response Randomisation

The Independent Data Monitoring Committee for EURAMOS-1 has recommended early release and dissemination of the results of the Poor Response randomisation. This proposal was ratified by the Trial Steering Committee.

This comparison investigated the efficacy and safety of an intensified CT regimen for patients (pts) with a "poor response" with a primary outcome measure of event free survival (EFS). 618 patients joined this randomisation from the four trials groups. 300 events have been observed to a target of 378.

The data show that adding ifosfamide and etoposide to MAP is associated with additional morbidity and has no effect on survival outcomes. Evidence from EURAMOS-1 does not support adaptation of postoperative chemotherapy based on histological response.

The data will be presented in detail at the Connective Tissue Oncology Society Meeting in Berlin on October 17, 2014.